Clonal Evolution of Myeloid Malignancies Treated With Microtransplantation: A Single‐Centre Experience
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von R Sammut und 8 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Hématologie, Centre Hospitalier Universitaire de Nice, Nice, France. Hauptthemen laut MEDLINE: Clonal Evolution, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Microtransplantation is a cellular therapy used in acute myeloid leukaemia and myelodysplastic syndromes as a maintenance therapy in patients ineligible for a regular allogeneic stem cell transplantation. We performed a monocentric retrospective study of acute myeloid leukaemia, myelodysplastic syndromes, and chronic myelomonocytic leukaemia patients who underwent microtransplantations at Nice University Hospital. We analysed the evolution of the disease mutational status after microtransplantation. We report 18 patients who underwent microtransplantation courses, with a total of 47 microtransplantations performed between February 2020 and June 2022. We observed long‐term remissions even in high‐risk patients. Founder mutations persisted throughout the follow‐up, whereas it was more variable for other nonfounder mutations, with most of the nonfounder mutations variant allele frequency decreasing over time. Safety data were reassuring; no graft versus host disease was recorded, and cytokine release syndromes were manageable. Relapses or progressions were associated with the emergence or increase of a TP53 mutated clone. Microtransplantation is a promising therapy for patients ineligible for regular allogeneic stem transplantation. Further larger and randomised studies are required to establish its place as a maintenance therapy in myeloid malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département d'Hématologie, Centre Hospitalier Universitaire de Nice, Nice, France.
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Lille, France.
- Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
- Laboratoire Central d'anatomie et de Cytologie Pathologique, Centre Hospitalier Universitaire de Nice, Nice, France.
- INSERM U1065, Centre de Médecine Moléculaire Méditerranéen, Université Nice Cote d'Azur, Nice, France.
- Université Cote d'Azur, Nice, France.
ORCID-Profile: R Sammut
Zitieren
APA
Sammut, R., Fenwarth, L., Pelissier, A., Marceau, A., Duployez, N., Benachour, S., Dadone, B., Cluzeau, T., & Loschi, M. (2025). Clonal Evolution of Myeloid Malignancies Treated With Microtransplantation: A Single‐Centre Experience. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70520
Vancouver
Sammut R, Fenwarth L, Pelissier A, Marceau A, Duployez N, Benachour S, et al. Clonal Evolution of Myeloid Malignancies Treated With Microtransplantation: A Single‐Centre Experience. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70520
BibTeX
@article{Sammut2025,
author = {Sammut, R and Fenwarth, L and Pelissier, A and Marceau, A and Duployez, N and Benachour, S and Dadone, B and Cluzeau, T and Loschi, M},
title = {Clonal Evolution of Myeloid Malignancies Treated With Microtransplantation: A Single‐Centre Experience},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70520}
}
EUVIMED